497 related articles for article (PubMed ID: 14633345)
1. Effect of therapy with insulin glargine (lantus) on glycemic control in toddlers, children, and adolescents with diabetes.
Hathout EH; Fujishige L; Geach J; Ischandar M; Maruo S; Mace JW
Diabetes Technol Ther; 2003; 5(5):801-6. PubMed ID: 14633345
[TBL] [Abstract][Full Text] [Related]
2. Glycemic control with insulin glargine as part of an ethnically diverse, community-based diabetes management program.
Philis-Tsimikas A; Zhang Q; Walker C
Am J Ther; 2006; 13(6):466-72. PubMed ID: 17122525
[TBL] [Abstract][Full Text] [Related]
3. Therapy with insulin glargine (Lantus) in toddlers, children and adolescents with type 1 diabetes.
Colino E; López-Capapé M; Golmayo L; Alvarez MA; Alonso M; Barrio R
Diabetes Res Clin Pract; 2005 Oct; 70(1):1-7. PubMed ID: 16126116
[TBL] [Abstract][Full Text] [Related]
4. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.
Mullins P; Sharplin P; Yki-Jarvinen H; Riddle MC; Haring HU
Clin Ther; 2007 Aug; 29(8):1607-19. PubMed ID: 17919543
[TBL] [Abstract][Full Text] [Related]
5. Flexible insulin therapy with glargine insulin improved glycemic control and reduced severe hypoglycemia among preschool-aged children with type 1 diabetes mellitus.
Alemzadeh R; Berhe T; Wyatt DT
Pediatrics; 2005 May; 115(5):1320-4. PubMed ID: 15867042
[TBL] [Abstract][Full Text] [Related]
6. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
Heller S; Koenen C; Bode B
Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
[TBL] [Abstract][Full Text] [Related]
7. Treatment with insulin glargine reduces asymptomatic hypoglycemia detected by continuous subcutaneous glucose monitoring in children and adolescents with type 1 diabetes.
Deiss D; Kordonouri O; Hartmann R; Hopfenmüller W; Lüpke K; Danne T
Pediatr Diabetes; 2007 Jun; 8(3):157-62. PubMed ID: 17550426
[TBL] [Abstract][Full Text] [Related]
8. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
Meneghini LF; Traylor L; Schwartz SL
Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
[TBL] [Abstract][Full Text] [Related]
9. Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-care-based analysis.
Sharplin P; Gordon J; Peters JR; Tetlow AP; Longman AJ; McEwan P
Cardiovasc Diabetol; 2009 Feb; 8():9. PubMed ID: 19220880
[TBL] [Abstract][Full Text] [Related]
10. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.
Rosenstock J; Schwartz SL; Clark CM; Park GD; Donley DW; Edwards MB
Diabetes Care; 2001 Apr; 24(4):631-6. PubMed ID: 11315821
[TBL] [Abstract][Full Text] [Related]
11. Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.
Johansen OE; Vanberg PJ; Kilhovd BK; Jørgensen AP
Vasc Health Risk Manag; 2009; 5(1):121-8. PubMed ID: 19436668
[TBL] [Abstract][Full Text] [Related]
12. Reduced severe hypoglycemia with insulin glargine in intensively treated adults with type 1 diabetes.
Garg SK; Paul JM; Karsten JI; Menditto L; Gottlieb PA
Diabetes Technol Ther; 2004 Oct; 6(5):589-95. PubMed ID: 15628812
[TBL] [Abstract][Full Text] [Related]
13. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
[TBL] [Abstract][Full Text] [Related]
14. Improved glycemic control with decreased hypoglycemia prevents long-term complications in type 2 diabetes patients: long-term simulation analysis using the "diabetes mellitus model".
Maxion-Bergemann S; Huppertz E; Jacobs LD; Müller E; Walleser S
Int J Clin Pharmacol Ther; 2005 Jun; 43(6):271-81. PubMed ID: 15968884
[TBL] [Abstract][Full Text] [Related]
15. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.
Yki-Järvinen H; Dressler A; Ziemen M;
Diabetes Care; 2000 Aug; 23(8):1130-6. PubMed ID: 10937510
[TBL] [Abstract][Full Text] [Related]
16. Will the use of insulin analogs improve glycemic control during adolescence?
Dunger DB
Pediatr Diabetes; 2003 Jun; 4(2):61-3. PubMed ID: 14655260
[No Abstract] [Full Text] [Related]
17. Initiation of insulin glargine in children and adolescents with type 1 diabetes.
Tan CY; Wilson DM; Buckingham B
Pediatr Diabetes; 2004 Jun; 5(2):80-6. PubMed ID: 15189493
[TBL] [Abstract][Full Text] [Related]
18. Insulin glargine improves hemoglobin A1c in children and adolescents with poorly controlled type 1 diabetes.
Jackson A; Ternand C; Brunzell C; Kleinschmidt T; Dew D; Milla C; Moran A
Pediatr Diabetes; 2003 Jun; 4(2):64-9. PubMed ID: 14655261
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
Seufert J; Pegelow K; Bramlage P
Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
[TBL] [Abstract][Full Text] [Related]
20. Deleterious outcomes after abrupt transition from insulin glargine to insulin detemir in patients with type 1 diabetes mellitus.
Kabadi UM
Clin Drug Investig; 2008; 28(11):697-701. PubMed ID: 18840012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
